Verastem Oncology (NASDAQ:VSTM) Stock In Focus After Q4 Earnings Update

March 16, 2023

Biopharmaceutical firm Verastem Oncology (NASDAQ:VSTM) is focused on the advancements of new medicines for cancer patients and yesterday, it was in focus after it announced its financial results for the full fiscal year and the three month period ended on December 31, 2022. It could be a good idea for investors to take a look at some of the highlights from the financial results. Trading Data On Wednesday, VSTM stock…

Read More >>